LTP·01learntopeptide
Longevity & bioregulatorsEvidence D3 cited

Vesugen

aka Vesugen bioregulator · Lys-Glu-Asp · KED peptide

Vesugen is a synthetic tripeptide composed of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the vascular system. It is designed to support endothelial function and microcirculation by modulating gene expression in vascular endothelial cells. Age-related vascular decline, characterised by endothelial dysfunction, reduced nitric oxide bioavailability, and impaired microcirculation, is a major contributor to cardiovascular disease and organ dysfunction. Vesugen is proposed to interact with DNA in endothelial cells to normalise transcription of genes involved in vascular homeostasis, including those regulating nitric oxide synthesis, angiogenesis, and endothelial integrity.

Molecular wt
390.39g/mol
Formula
C15H26N4O8
CAS
204271-66-9
Half-life
2 h
estimated
Tmax
1 h
Route
Oral or subcutaneous
PubChem
87571363

Sequence

One-letter3 residues

KED

Three-letter

Lys-Glu-Asp

Read this before quoting the sequence
Tripeptide L-lysyl-L-glutamyl-L-aspartic acid, one of the Khavinson 'short peptide bioregulators'. The Vesugen = Lys-Glu-Asp identity is stated in an English-language PubMed-indexed paper from the originating group (Khavinson et al, Bull Exp Biol Med 2012: 'vesugen (Lys-Glu-Asp)'). PubChem does not carry 'Vesugen' as a synonym on the Lys-Glu-Asp record, so the chemistry below is that of the tripeptide, matched by name rather than by a registry cross-reference.
Source ↗

Mechanism of action

Vesugen (Lys-Glu-Asp) is theorised to penetrate endothelial cell membranes and interact with specific DNA sequences to modulate gene expression related to vascular function. Proposed targets include genes involved in endothelial nitric oxide synthase (eNOS) expression, prostacyclin synthesis, and endothelial cell adhesion molecule regulation. By potentially restoring youthful gene expression patterns in aging vasculature, Vesugen may support nitric oxide-dependent vasodilation, reduce endothelial inflammation, and improve microcirculatory blood flow.

What the evidence actually shows

Grade D

Evidence for Vesugen consists primarily of preclinical studies and observational data from Russian clinical practice. In vitro studies have shown effects on endothelial cell gene expression, and animal models have demonstrated improvements in microcirculation. No controlled human clinical trials meeting international standards have been published.

Regulatory status

Status
Not an approved medicine anywhere. No Drugs@FDA record, no DailyMed SPL, no EMA authorisation. Marketed in Russia and internationally as a dietary supplement / 'peptide bioregulator' rather than a drug.
Clinical stage
No ClinicalTrials.gov-registered trials. The only human data are small uncontrolled Russian-language gerontology reports (e.g. Adv Gerontol 2015, n=32, PMID 26390612), which report both claimed anti-ageing effects and prooxidant activity and inhibition of haematopoiesis.
WADA
Not named on the WADA 2026 Prohibited List.
Source ↗

Pharmacokinetics

Half-life
2 h
Tmax
1 h
Absorption
subcutaneous
Elimination
renal
Washout
2 days
Low-confidence pharmacokinetics
These figures are recorded as estimated rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Handling and storage

No compound-specific stability data exists
No approved product and no regulatory label anywhere; no compound-specific stability data in any indexed publication. Ported storage text ('-20C ~24 months lyophilised; 2-8C ~4 weeks reconstituted') is generic peptide-handling boilerplate that was applied identically across many compounds in this dataset. It is not sourced to this compound. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

References (3)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Longevity & bioregulators

Acein
A research peptide that inhibits connective tissue growth factor (CCN2/CTGF), a key mediator of tissue fibrosis. Targets the fundamental fibrotic pathway involved in organ aging and disease.
Carnosine
A naturally occurring dipeptide (beta-alanine + histidine) with potent anti-glycation, antioxidant, and pH-buffering properties. Acts as an AGE inhibitor, preventing cross-linking of proteins that accelerates tissue aging.
Cortagen
Cortagen is a short synthetic bioregulator peptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to target the adrenal cortex, supporting the regulation of cortisol production and adrenal gland function. Bioregulator peptides are based on the concept that short peptide sequences derived from or mimicking endogenous tissue-specific peptides can restore gene expression patterns in aging or damaged tissues. Cortagen is proposed to normalise adrenal cortex function by interacting with DNA and modulating transcription of genes involved in steroidogenesis. While the bioregulator concept has theoretical appeal, the evidence base consists primarily of preclinical studies and observational reports from Russian clinical practice.